Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Epistemonikos ID: c67b564eeb4100dc1a449e7dc5ca7587ab9c65be
First added on: Feb 19, 2024